Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.

Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.

Apr 3, 2025 · Adalvo strengthens its specialty generics portfolio with the dossier readiness of Tofacitinib XR (11mg). Backed by a ready-to-register EU CTD dossier, the extended-release (XR) formulation expands Adalvo’s offering and ensures broader treatment...

Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.

Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.

Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward. You need people that has the industry know how and internal capabilities that align with your business goals.

Jun 23, 2022 · Adalvo is now able to offer over 100 tailor-made products to our partners. As part of our growth journey, our focus has always been to bring high-value, differentiated products, covering diverse technology platforms.

Jun 13, 2024 · Adalvo announces the successful DCP approval for Liraglutide pre-filled pen, marking it as the first generic approval in the EU. As a bioequivalent version of Victoza® pre-filled pen, indicated for the treatment of type 2 diabetes, this peptide drug achieved global sales exceeding $4.8 billion in 2023, as reported by IQVIA.

Adalvo is a global pharmaceutical company with a declared purpose to make a difference for patients around the world driven by our smart collaboration network and commitment to deliver highest quality differentiated products and services to our partners.